Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.

CONCLUSIONS: Maternal immunization with the trivalent GBS vaccine in US women had a favorable safety profile, elicited antibodies that were transplacentally transferred and persisted in infants for a minimum of 3 months.
CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT02046148.
PMID: 32883555 [PubMed - as supplied by publisher]

Source: Vaccine - August 30, 2020 Category: Allergy & Immunology Authors: Swamy GK, Metz TD, Edwards KM, Soper DE, Beigi RH, Campbell JD, Grassano L, Buffi G, Dreisbach A, Margarit I, Karsten A, Henry O, Lattanzi M, Bebia Z Tags: Vaccine Source Type: research